Navigation Links
18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkin's Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
Date:9/15/2009

s Control 6.9 months 6.9 months P Value 0.54 (HR = 0.88) 0.3 (HR = 0.82)

"We continue to be impressed by the durability of responses in the pixantrone treatment arm which seemed to improve during the study follow up period, compared to the standard chemotherapy recipients - whose responses and duration of response are largely unchanged from the initial assessment period," noted James A. Bianco, M.D., Chief Executive Officer of CTI. "We are also encouraged by the increase in the overall survival estimates, especially among those patients whose histologic diagnosis was verified by independent pathologists where 40% of pixantrone recipients were alive, compared to 27% for standard chemotherapy at the 1 year landmark period. We plan to submit these updated safety and efficacy data to our NDA as part of the 120 Day update."

The FDA typically receives updated clinical study data 120 days following the initial NDA submission.

The most common (incidence greater than or equal to 20%) adverse reactions reported for pixantrone-treated subjects were neutropenia, infection, anemia, leucopenia, thrombocytopenia, asthenia, pyrexia, and cough.

Pixantrone has been accepted for standard review by the Food & Drug Administration (FDA), with fast track status with a Prescription Drug User Fee Act (PDUFA) date of April 23, 2010.

           BioCentury's NewsMakers in the Biotech Industry Conference
                CTI Presentation: Wednesday, September 16, 2009
       10:30 a.m. Eastern /7:30 a.m. Pacific /6:30 p.m. Central European
             Audio webcast with slides at www.celltherapeutics.com

About the EXTEND (PIX301) Clinical Trial

The EXTEND clinical trial is a phase III single agent trial of pixantrone for patients with relapsed or refractory, aggressive nonHodgkin's lymphoma who recei
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
3. Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study at ARVO 2009 Annual Meeting
4. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
5. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
6. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
7. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
8. Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
9. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
10. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
11. 12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
(Date:12/17/2014)... , December 17, 2014 ... nothing less than a hub of information concerning the biopharmaceutical ... A further addition to the recently launched institutional ... and has now been enriched by a new chapter in ... A richly detailed and panoramic hub on the ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... 2011 Henry Schein, Inc. (NASDAQ: ... services to office-based practitioners, announced today that Ferdinand ... the CL King 9th Annual Best Ideas Conference 2011. The ... New York City. Henry Schein,s presentation is ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... for human disease, reported positive data from a recently ... dual inhibitor of the sodium glucose transporters 1 and ... effects on multiple parameters of glycemic control and cardiovascular ...
Cached Medicine Technology:Henry Schein to Present at the CL King 9th Annual Best Ideas Conference 2011 2LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects 2LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects 3LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects 4
(Date:12/19/2014)... 18, 2014 (HealthDay News) -- Being in good shape seems ... They looked at data from more than 57,000 Americans, ... treadmill tests between 1991 and 2009. Those in the ... having high blood pressure at the start of the study, ... levels of fitness. Of the more than 8,000 people ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, ... ibuprofen, might slightly reduce your risk of developing a ... ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to reduce ... percent, the researchers concluded after reviewing nine prior studies. ... exposure. These painkillers "have potential as ...
(Date:12/17/2014)... While countless companies tempt patients to buy hCG ... of their purchase. Not only is the sale of hCG ... patients who buy hCG online are typically receiving products that ... real hCG present. Illegal internet hCG is typically manufactured outside ... and may contain unknown fillers that can pose very serious ...
(Date:12/17/2014)... December 17, 2014 HeartMath® Inc., ... on stress, heart rate variability (HRV), heart coherence ... its extensive HRV databases and algorithms to chipset ... will enable HeartMath’s partners to offer its HRV ... research, as well as its normative HRV databases ...
(Date:12/17/2014)... Hill, IL (PRWEB) December 17, 2014 ... 2015 Awards celebrate the best of the best in ... The award is only given to communities and agencies ... through the SeniorAdvisor.com site. Of the nearly 100,000 providers ... this award. Winners of the SeniorAdvisor.com Best of 2015 ...
Breaking Medicine News(10 mins):Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3
... analysis of strains responsible for common cold and other ... the virusROCKVILLE, Md., Feb. 12 A team of ... University of Maryland School of Medicine and ... they have sequenced and analyzed the genomes of all ...
... Today, the Medicaid Health Plans of America (MHPA) ... Medicaid health plans, applauded House and Senate negotiators who ... Reinvestment Act Conference Report that will maintain coverage for ... in this agreement will allow states to continue coverage ...
... Tobacco Prevention CampaignsWASHINGTON, Feb. 12 The ... Myers, President, Campaign for Tobacco-Free Kids:(Logo: ... provide powerful new evidence that tobacco marketing ... campaigns prevent smoking. These studies send ...
... in Sweden doesn,t transfer to U.S., study finds , , THURSDAY, ... whether smokeless tobacco can help smokers quit cigarettes, contends a ... quit smoking by using snus, a form of moist, powdered ... more popular among male smokers, and Swedish men have higher ...
... for treatments deemed safe and effective. The stimulus ... set by a new bureaucracy, the Federal Coordinating Council ... a U.K. board discussed in Tom Daschle,s book, ... treatments using a formula that divides the cost of ...
... Venture Capitalists to Identify Investment Opportunities in the Multi-Billion ... N.Y., Feb. 12 The equity markets and the ... young medical device companies and private equity investors to ... For venture capitalists, the "New Economy " ...
Cached Medicine News:Health News:Complete Genomes of All Known Human Rhinoviruses are Published 2Health News:Complete Genomes of All Known Human Rhinoviruses are Published 3Health News:Medicaid Health Plans of America Lauds Stimulus Bill's Conference Agreement Which Provides $90 Billion in Medicaid Relief for Nation's Most Vulnerable Citizens 2Health News:New CDC Study Shows Tobacco Marketing Influences Kids to Smoke, Underscores Need for FDA Regulation of Tobacco Products 2Health News:New CDC Study Shows Tobacco Marketing Influences Kids to Smoke, Underscores Need for FDA Regulation of Tobacco Products 3Health News:New CDC Study Shows Tobacco Marketing Influences Kids to Smoke, Underscores Need for FDA Regulation of Tobacco Products 4Health News:Smokeless Tobacco May Not Help Smokers Quit 2Health News:MedTech Investing Conference (8th Annual) May 6-7, 2009 2Health News:MedTech Investing Conference (8th Annual) May 6-7, 2009 3
... Cyclopedic Medical Dictionary 20th edition ... and based on F.A. Daviss ... on PDA. It defines over ... and health-care professionals, patients and ...
The American Heritage® Stedman's Medical Dictionary is a work for consumers and patients concerned with medicine and health today....
ICDMeister is an electronic reference containing 15,000 of the 2006 ICD-9-CM diagnosis codes. Use whichever of the four different approaches for finding codes that you ....
... gives the Physician, the Administrator and the ... Coder Web Edition over the internet. The ... of the Enterprise Server but leaves all ... upgrades and white glove user support are ...
Medicine Products: